Prostate specific antigen testing among the elderly--when to stop? - Wikidata - awgldk - TriplyDB

Prostate specific antigen testing among the elderly--when to stop?

Prostate specific antigen testing among the elderly--when to stop?

http://www.wikidata.org/entity/Q34604893

about

Early detection of prostate cancer: AUA Guideline.Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.Expected population impacts of discontinued prostate-specific antigen screening.Gleason 6 Prostate Cancer: Translating Biology into Population Health.Primary care providers' perspectives on discontinuing prostate cancer screening.Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.Should prostate-specific antigen screening be offered to asymptomatic men?Informed prostate cancer risk-adjusted testing: a new paradigm.American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.What's new in screening in 2015?Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns.Gleason score stratification according to age at diagnosis in 1028 men Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men

P2860

Q33608474-9AAAC92D-3615-4784-A5B9-00F146AD1D02 Q33676037-DAAD5B60-B83C-4EF2-8AAF-F90FE8ACD9FA Q34086557-BB972954-CFBC-4A4D-BB0A-6E7C5FDD73DD Q34458237-02906B74-F126-464F-B3C7-C059FE86EA03 Q34470640-88C66857-65FB-49EA-B0AE-45770EF1B583 Q36188117-8403972E-704B-4B44-93BD-FD7E5D1536EA Q36767094-D4650BC9-4DE9-4EAF-B237-EDFC938F1E00 Q36831317-45BE4A11-E03A-4973-8556-79C532389A92 Q37103771-A8CAEEAB-8D1F-4A3F-8955-D300E17A039F Q37619443-3BF9CD78-E414-478A-88C1-EC74CEA9CCE7 Q37774352-F9307A01-E052-40ED-B2A9-37B8351B9B43 Q38063556-F0DB0A28-3676-4377-863F-34A13C7CDECD Q38127277-62E8755D-42C0-4368-AE69-5954E0A84E98 Q38871819-DA84AFDD-33F0-4591-80E5-8CD08ED81E4A Q39937201-9CB430B3-E4F9-439C-8774-5BB83B00E0D0 Q40350242-BEAEA314-1026-41FE-8F34-FC99EDC042B0 Q42395953-C18AD477-B891-4930-B18E-629DCA2CEBF6 Q57118155-BD4B735B-CB3F-4114-A221-124760E0FC8E

P2860

Prostate specific antigen testing among the elderly--when to stop?

http://www.wikidata.org/entity/Q34604893

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prostate specific antigen testing among the elderly--when to stop?

@ast

Prostate specific antigen testing among the elderly--when to stop?

@en

Prostate specific antigen testing among the elderly--when to stop?

@nl

type

label

Prostate specific antigen testing among the elderly--when to stop?

@ast

Prostate specific antigen testing among the elderly--when to stop?

@en

Prostate specific antigen testing among the elderly--when to stop?

@nl

prefLabel

Prostate specific antigen testing among the elderly--when to stop?

@ast

Prostate specific antigen testing among the elderly--when to stop?

@en

Prostate specific antigen testing among the elderly--when to stop?

@nl

P1433

Q34604893-1B961200-D824-4EAE-9EDF-7A2489A931CC

P1476

Q34604893-2E0D5812-583F-406F-9E93-B11F202C7804

P2093

Q34604893-2D5338CA-F2A6-4ACE-8606-C3D324C604BA

Q34604893-320170F3-1941-4D75-8381-4B6FD092097A

Q34604893-54B9B4AA-BCD2-4B47-A071-DE2669EDEFC9

Q34604893-55050366-4F87-4357-8C57-B0F825ECAB87

Q34604893-8DBE5A0D-8D0E-4762-B809-0B038E882E66

Q34604893-96D3D083-C5E6-4DD7-8AB7-35B5FA37BAA2

Q34604893-EA40807C-88EB-49C3-A81E-76318EF72A3A

P2860

Q34604893-0E6E9E79-385F-42C5-840B-989064C359CD

Q34604893-578623FC-50DE-4297-8BDC-AE6D6ADF5A45

Q34604893-5C24D0B4-B96A-46E5-ACA7-1B9611344581

Q34604893-6F710863-E6F1-4058-9657-0689FBE2BFCC

Q34604893-9D8E5535-13EF-4E57-A157-51475F8DE1D2

Q34604893-C16E3224-D3B8-46EE-B18F-FE5EDAF6DF32

Q34604893-C20F8EF0-FB79-44E0-8A32-3960A54DF07B

Q34604893-C39AB5A5-7B29-4953-BC85-9F1715635B14

Q34604893-C928B315-5EBC-429E-8B64-38EBB4624AB4

Q34604893-CE6AE99B-5E76-4695-87BA-6CD629F1732D

P304

Q34604893-CE95D0E0-6ABC-4CC3-90B7-D10E7046908D

P31

Q34604893-ECCF5B2A-8A18-4888-BAEC-91346067F296

P356

Q34604893-A7319044-A45F-41D3-816C-0BA18D29E550

P407

Q34604893-39EB447A-2058-4816-92C7-7D03FF8AE4EE

P433

Q34604893-79BB4225-3ACD-4DD0-B3DA-0ECAE2303DDC

P478

Q34604893-42A66F1F-83EA-4045-B195-252418E15944

P50

Q34604893-1D0FF09C-5544-442E-B474-6CE66E78C85B

P577

Q34604893-2758A4FB-5AB4-45DC-A4E9-22E78D45ECF9

P5875

Q34604893-9506B8B5-46E4-4661-8520-4C475D36ACF6

P698

Q34604893-1B7552BE-6E14-4152-A108-3F2844860D9E

P932

Q34604893-E206716A-D865-4AF8-8276-1B994AABD907

P356

J.JURO.2008.11.117

P1433

The Journal of Urology

P1476

Prostate specific antigen testing among the elderly--when to stop?

@en

P2093

Anna Kettermann

http://www.w3.org/2001/XMLSchema#string

Bruce J Trock

http://www.w3.org/2001/XMLSchema#string

E Jeffrey Metter

http://www.w3.org/2001/XMLSchema#string

H Ballentine Carter

http://www.w3.org/2001/XMLSchema#string

Luigi Ferrucci

http://www.w3.org/2001/XMLSchema#string

Patricia Landis

http://www.w3.org/2001/XMLSchema#string

Stacy Loeb

http://www.w3.org/2001/XMLSchema#string

P2860

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

A piece of my mind. Winners and losers.

American Cancer Society guidelines for the early detection of cancer.

20-year outcomes following conservative management of clinically localized prostate cancer.

The changing face of prostate cancer.

Surgical management of high risk prostate cancer: the Mayo Clinic experience.

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Prostate-specific antigen levels as a predictor of lethal prostate cancer.

P304

1606-14; discussion 1613-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2008.11.117

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P50

Edward M Schaeffer

P577

2009-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24043312

http://www.w3.org/2001/XMLSchema#string

P698

19246059

http://www.w3.org/2001/XMLSchema#string

P932

2668165

http://www.w3.org/2001/XMLSchema#string